摘要
目的观察更年期女性使用重组人甲状旁腺素(1-34)治疗后血清骨硬化蛋白(SO)水平的变化,探讨SO与雌二醇、骨密度等指标的相关性。方法选择更年期骨质疏松女性58例,更年期正常对照组50例。骨质疏松组皮下注射PTH 20 ug/d,同时口服钙片500 mg/d,分别于治疗6个月、12个月时检测患者血钙、磷、骨密度、血清ALP、雌二醇及SO等指标。结果治疗前骨质疏松组血清SO含量显著高于正常对照组,经rhPTH(1-34)治疗6个月和12个月后,骨质疏松组血清SO水平较治疗前均明显下降[6月时:(10.2±1.21)vs.(13.1±1.41)pg/mL;12月时:(7.81±1.12)vs.(13.1±1.41)pg/mL,P<0.05]。相关性分析显示,血清SO水平与雌二醇、骨密度呈负相关,与年龄、绝经年限呈正相关(P<0.05)。结论更年期骨质疏松患者血清SO水平明显升高,经rhPTH(1-34)治疗后血清SO水平显著下降。血清SO水平与雌二醇、骨密度密切相关,提示SO在更年期骨质疏松的发生发展中起着重要作用。
[ Objective ] To investigate the changes in serum sclerostin （SO） in menopausal women with osteoporo-sis after treatment with recombinant human parathyroid hormone （1-34） [rhPTH（1-34）], and to explore the relation-ship of serum SO with estradiol （E2） and bone mineral density （BMD）. [Methods] Menopausal women were dividedinto normal BMD group （n =50） and osteoporosis group （n =58）. Body mass index （BMI）, alkaline phosphatase （ALP）,serum E2, calcium, phosphate, and SO were determined in both groups. The patients in osteoporosis group weretreated with rhPTH （1-34） 20ug/d by subcutaneous injection and oral calcium 500 mg/d for 12 months. Serum calci-um, serum phosphate, BMD, serum ALP, serum E2 and SO were determined in osteoporosis group by 6 months and12 months of treatment. [Results] Serum level of SO in osteoporosis group was significantly higher as comparedwith normal BMD group （P 〈0.05）. Serum SO decreased significantly after treatment of rhPTH （1-34） by 6 monthsand 12 months [after 6 months： （10.2±1.21） vs. （13.1±1.41） pg/mL; after 12 months： （7.81±1.12） vs. （13.1±l.41）pg/ml, P 〈0.05]. E2 and BMD were negatively correlated with serum SO, age and postmenopausal years were positivelycorrelated with serum SO （P 〈0.05）. [ Conclusions ] Serum SO increased significantly in menopausal women with os-teoporosis, and decreased gradually with treatment of rhPTH （1-34）. Serum SO was related to E2 and BMD, and itmay participate in the development of menopause osteoporosis.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2014年第15期58-61,共4页
China Journal of Modern Medicine
